Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?

Executive Summary

Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics

You may also be interested in...



The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills

The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009

The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills

The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009

Orphan Biologics Should Get Two Extra Years Of Exclusivity, NORD Says

Organization tells Rep. Waxman it still "wholeheartedly" supports his bill, but is planning its legislative approach around longer brand exclusivity.

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel